Schlenk, R. F., Montesinos, P., Romero-Aguilar, A., Vrhovac, R., Patkowska, E., Kim, H.-J., … Erba, H. P. (2023). IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL. In BONE MARROW TRANSPLANTATION (Vol. 58, pp. 22–23).

Schlenk, Richard F., Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elzbieta Patkowska, Hee-Je Kim, Pavel Zak, et al. “IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL.” In BONE MARROW TRANSPLANTATION, 58:22–23, 2023.

Schlenk RF, Montesinos P, Romero-Aguilar A, Vrhovac R, Patkowska E, Kim H-J, et al. IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL. In: BONE MARROW TRANSPLANTATION. 2023. p. 22–3.

Schlenk, Richard F., et al. “IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL.” BONE MARROW TRANSPLANTATION, vol. 58, no. SUPP1, 2023, pp. 22–23.

Schlenk RF, Montesinos P, Romero-Aguilar A, Vrhovac R, Patkowska E, Kim H-J, Zak P, Wang P-N, Hanyok J, Liu L, Kamel YM, Benzohra A, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Perl AE, Levis MJ, Erba HP. IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL. BONE MARROW TRANSPLANTATION. 2023. p. 22–23.